GlaxoSmithKline recently became the 14th biopharma company to switch up its approach to distributing drugs purchased via the federal 340B program for low-income individuals.
Effective April 1, GSK said it will ship products purchased at the lower, 340B prices exclusively to locations registered as a 340B covered entity or affiliate…
